Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis

Trial Profile

Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Japanese cedar pollen allergy immunotherapy ALK Abello/Torii Pharmaceutical (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 24 Jun 2019 Results presented in an ALK-Abello media release.
    • 24 Jun 2019 According to an ALK-Abello media release, the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities. The data used in the filing include results from the Phase III clinical trial finalised in 2017.
    • 27 Sep 2017 According to ALK's media release, Japan's Ministry of Health, Labour and Welfare has approved the New Drug Application submitted by its partner Torii Pharmaceutical Co Ltd, for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, which will be branded CEDARCURE.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top